-
12 June 2025 10:17:15
- Source: Sharecast
12 June 2025
Genflow Biosciences Plc
Results of Annual General Meeting
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
|
Ordinary Resolutions |
Votes for |
% of votes cast for |
Votes Against |
% of votes cast against |
Total votes cast |
Votes withheld |
|
1. To receive and consider the Annual Report and Accounts for the year ended 31 December 2024 together with the Directors' Report and Auditors' Report thereon. |
152,365,311 |
99.5%
|
312
|
0.0%
|
152,365,623
|
753,187
|
|
2. To approve the directors' remuneration report for the financial period ended 31 December 2024 set out in the audited accounts for the financial period ended 31 December 2024. |
152,069,752
|
99.3%
|
270,744
|
0.2%
|
152,340,496
|
778,314
|
|
3. To re-appoint PKF Littlejohn LLP as auditors of the Company and to authorise the Directors of the Company to fix their remuneration. |
151,451,787
|
98.9%
|
121,889
|
0.1%
|
151,573,676
|
1,545,134
|
|
4. To re-elect Tamara Joseph as a Director of the Company. |
151,449,590
|
98.9%
|
206,583
|
0.1%
|
151,656,173
|
1,462,637
|
|
5. To re-elect Dr Guy-Charles Fanneau de La Horie as a Director of the Company. |
151,448,295
|
98.9%
|
207,469
|
0.1%
|
151,655,764
|
1,463,046
|
|
6. To re-elect Dr Eric Leire as a Director of the Company. |
152,668,756
|
99.7%
|
192,686
|
0.1%
|
152,861,442
|
257,368
|
|
7. To re-elect Dr Yassine Bendiabdallah as a Director of the Company. |
151,442,263
|
98.9%
|
213,734
|
0.1%
|
151,655,997
|
1,462,813
|
|
8. To re-elect Dr Peter King Lewis as a Director of the Company. |
152,636,489
|
99.7%
|
192,843
|
0.1%
|
152,829,332
|
289,478
|
|
9. To authorise the Directors to allot shares in the Company. |
132,658,404
|
86.6%
|
19,655,616
|
12.8%
|
152,314,020
|
804,790
|
|
Special Resolution |
Votes for |
% of votes cast for |
Votes Against |
% of votes cast against |
Total votes cast |
Votes withheld |
|
10. To disapply statutory pre-emption rights. |
132,698,727
|
86.7%
|
18,861,048
|
12.3%
|
151,559,775
|
1,559,035
|
|
Contacts
Genflow Biosciences |
Harbor Access |
|
Dr Eric Leire, CEO |
Jonathan Paterson, Investor Relations |
|
+32-477-495-881 |
+1 475 477 9401 |
|
|
Jonathan.Paterson@Harbor-access.com |
|
|
|
|
Corporate Brokers |
|
|
Capital Plus Partners Ltd |
|
|
Jon Critchley, +44 0203 821 6168 |
|
|
|
|
About Genflow
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.
Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.